Driving theory test to include CPR first aid questions
All road users are being encouraged to learn the basics and know how to use a defibrillator in an emergency.
It's hoped the questions, which will be added to the car and motorcycle theory test in early 2026, could prevent avoidable deaths.
Drivers are often first on the scene when someone suffers a cardiac arrest, says the DVSA.
Adding the information into the official learning materials means that the 2.4 million learner drivers who take their theory test each year will have a better understanding of the skills to use in an emergency, it says.
Learning materials have already been updated with the new content, including questions such as "Who can use a public access defibrillator?" - the answer being "everyone".
A defibrillator gives a jolt of energy to the heart, which can help get it beating normally.
The devices are designed to be user-friendly, with clear instructions.
If CPR is given and a defibrillator used within the first minutes of collapse, survival rates could be as high as 70%, evidence suggests. Without it, fewer than one in 10 survive.
If someone is unconscious and not breathing normally, call 999 and start CPR straight away.
This can be "hands-only" CPR to deliver timely chest compressions to get blood pumping.
One of the new theory test questions is about the correct depth to push down.
To carry out a chest compression, the NHS advises:
kneel next to the person and place the heel of your hand on the breastbone at the centre of their chest. Place the palm of your other hand on top of the hand that's on their chest and interlock your fingers
position yourself so your shoulders are directly above your hands
using your body weight (not just your arms), press straight down by 5 to 6cm (2 to 2.5 inches) on their chest
keeping your hands on their chest, release the compression and allow their chest to return to its original position
repeat these compressions at a rate of 100 to 120 times a minute until an ambulance arrives or for as long as you can
James Cant, chief executive of Resuscitation Council UK, said: "We're delighted to be working with the DVSA and other partners to introduce CPR and defibrillator awareness into the driving theory test.
"By embedding these life-saving skills into such a widely taken assessment, we can help ensure that more people, from all communities, gain the knowledge and confidence to act during a cardiac arrest."
10,000 extra driving tests a month to clear backlog
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
18 minutes ago
- Medscape
Drug Combinations for CVDs Tied to Bullous Pemphigoid Risk
TOPLINE: A case-control study revealed that combinations of drugs for cardiovascular diseases and hypertension were frequently prescribed before a diagnosis of bullous pemphigoid (BP), but the risk associated with combinations did not exceed that associated with individual agents. The most common drug combinations included angiotensin-converting enzyme (ACE) inhibitors with statins and antiplatelets with statins. METHODOLOGY: Researchers conducted a nested case-control study using healthcare records from the Clinical Practice Research Datalink between 1998 and 2021 and analysed 16,844 BP cases and 79,493 age- and sex-matched control individuals having no BP diagnosis at the index date (the first date a BP diagnosis code was recorded). Association rule mining (ARM) identified the 10 most common drug class or active substance pairs prescribed to cases or control individuals on the same day and within 6 months before the index date. In the sensitivity analysis, researchers identified medication pairs prescribed within 30 days of each other and during the 6 months preceding the index date. Researchers quantified how often two drugs are co-prescribed compared with their independent prescribing by calculating a lift. They then derived the fold change (FC) as the ratio of a lift in cases vs control individuals. The analysis included multivariable conditional logistic regression to estimate the risk for BP following drug combinations and their constituent drugs. TAKEAWAY: The most frequent drug combinations associated with an increased risk for BP were ACE inhibitors-statins (FC of the lifts in the main analysis vs sensitivity analysis: 1.31 vs 1.18), antiplatelets-statins (1.23 vs 1.11), proton pump inhibitors (PPI)-antiplatelets (1.22 vs 1.14), PPI-statins (1.22 vs 1.14), and ACE inhibitors-antiplatelets (1.20 vs 1.09). For drug substances, combinations with a greater lift in BP cases were simvastatin-ramipril (FC, 1.30), simvastatin-aspirin (FC, 1.21), and ramipril-aspirin (FC, 1.19). After adjusting for BP-associated drugs, the Charlson Comorbidity Index, and relevant confounders, the increased risk remained significant for these drug class combinations: antiplatelets-statins (odds ratio [OR], 1.20), ACE inhibitors-statins (OR, 1.16), PPI-statins (OR, 1.22), ACE inhibitors-antiplatelets (OR, 1.26), and PPI-antiplatelets (OR, 1.43; P < .001 for all). The risk for BP associated with these frequently prescribed drug combinations was lower than the risk linked to each constituent drug at both class and substance levels. In both main and sensitivity analyses, patients who developed BP were more likely than control individuals to have received combinations of cardiovascular or antihypertensive drugs before diagnosis. IN PRACTICE: "The ARM algorithm exploratory analysis identified the most commonly prescribed drug combinations prior to BP. Logistic regression confirmed drug combinations for CVDs [cardiovascular diseases] or hypertension associated with increased BP risk," the authors wrote. "The increased BP risk following reported combinations was modest and was not greater than their constituent drugs. Given that the number of patients with BP is low, we do not suggest avoiding the reported drugs but instead being on the lookout for any skin reactions following treatments for CVDs or hypertension," they concluded. SOURCE: This study was led by Mikolaj Swiderski, University of Nottingham, Nottingham, England. It was published online on August 06, 2025, in Clinical and Experimental Dermatology. LIMITATIONS: The ARM algorithm considered only the frequency of prescriptions to obtain drug combinations. Additionally, the algorithm demonstrated limited clinical value, linking only half of the inferred drug class combinations with BP and failing to capture the sequence or precise timing of prescriptions. It also lacked dosage and treatment duration data, and as an exploratory tool, ARM could not establish causal relationships between drug exposures and the risk for BP. DISCLOSURES: This research was supported by the National Institute for Health and Care Research grant via the Research for Patient Benefit Programme. Swiderski reported receiving salary funding from this grant. Another author reported receiving salary funding from King's College London, University of Nottingham, and the National Institute for Health and Care Research East Midlands scholarship scheme. Additional disclosures are noted in the original article. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
18 minutes ago
- Medscape
A1c Testing in EDs Can Spot Undiagnosed Diabetes Cases
TOPLINE: Among adults aged 30 years or older presenting to the emergency department (ED) without a prior diagnosis of type 2 diabetes (T2D), A1c testing combined with the Finnish Diabetes Risk Score (FINDRISC) identified a substantial proportion with prediabetes or diabetes — especially among those from ethnically diverse populations. METHODOLOGY: Researchers in England conducted a prospective study from December 2021 to December 2022 to determine the prevalence of glucose intolerance among 1382 individuals aged 30 years or older (45.1% men) who did not have a known diagnosis of diabetes and presented to the ED of a hospital in Manchester. They also tested the utility of the FINDRISC in predicting the risk for diabetes in high-risk individuals. Data on demographics, lifestyle factors, physical measurements, and A1c levels were collected, and the FINDRISC assessment was conducted by trained staff. Patients were classified as those having normal glucose tolerance, prediabetes, or diabetes according to both National Institute for Health and Care Excellence (NICE) and American Diabetes Association (ADA) guidelines. TAKEAWAY: On the basis of the NICE criteria, 80.1% of attendees had normal glucose tolerance, 11.6% had prediabetes, and 8.3% had diabetes; on the basis of the ADA criteria, the corresponding percentages were 61.3%, 30.4%, and 8.3%, respectively. Each unit increase in the FINDRISC was linked to an 8% (5%-12%) higher risk for prediabetes and a 16% (10%-23%) higher risk for diabetes, as per the NICE criteria, with similar findings seen for the ADA criteria as well; the risk remained elevated even after adjustment for confounders. Compared with White individuals, British South Asian and other minority groups showed nearly twice the risk for prediabetes (relative risk ratio [RRR], 1.94; 95% CI, 1.11-3.38) and three times the risk for diabetes (RRR, 2.80; 95% CI, 1.61-4.84). IN PRACTICE: "The considerable prevalence of undiagnosed diabetes within our patient population highlights the critical need for routine HbA1c screening in this setting, which may be the only place where hard-to-reach individuals may attend for healthcare," the authors wrote. SOURCE: This study was led by Edward B. Jude, Tameside and Glossop Integrated Care, NHS Foundation Trust, Manchester, England. It was published online on August 06, 2025, in Diabetes Therapy. LIMITATIONS: The accuracy of A1c testing can be affected by conditions altering the quality or quantity of haemoglobin, such as anaemia or haemoglobinopathies, potentially leading to an underestimation of diabetes prevalence. Selection bias may exist as the study focused only on patients who underwent bloodwork in the ED. The single-centre nature of the study limited the generalisability of the results. DISCLOSURES: This study received partial funding from Sanofi Pharmaceuticals and Novo Nordisk. One author was supported by the 4Ward North Wellcome Trust Clinical Research Training Fellowship, and another author declared receiving travel and research grants from the funding agencies and other sources. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
18 minutes ago
- Medscape
Graft Failure Risk Rises in Paediatric Kidney Retransplants
TOPLINE: In paediatric kidney transplant recipients, the risk for graft failure increased with each subsequent transplantation. After the second transplant, older donor age, transplantation from a deceased donor, shorter survival of the primary graft in non-sensitised recipients, higher panel-reactive antibody (PRA) levels, and an increasing number of human leucocyte antigen DR (HLA-DR) mismatches predicted a higher risk for graft failure. METHODOLOGY: Researchers analysed data from a European registry to determine the incidence and risk factors for graft failure and death after repeat kidney transplantation in paediatric recipients across Eurotransplant countries. They included 4527 primary paediatric kidney transplant recipients (median age, 11 years; 41% girls), of whom 1155 underwent a second, 259 a third, and 41 a fourth kidney transplantation. The median follow-up duration for the first, second, third, and fourth kidney transplantation was 8.83, 6.67, 5.75, and 5.58 years, respectively. The probability of graft failure (the need for dialysis or retransplantation) and death with a functioning graft was analysed in kidney transplantation recipients. Patient data collection included recipient sex and age; country; transplantation dates; PRA levels; primary kidney disease; graft failure dates; donor source, age, and sex; and the number of HLA mismatches. TAKEAWAY: The risk for graft failure increased with each subsequent kidney transplant, with 5-year rates of 15% after the first, 24% after the second, 30% after the third, and 40% after the fourth transplant. The risk for graft failure or death with a functioning graft was the highest in the first month after primary kidney transplantation and increased even further after each subsequent transplantation. After the second transplant, transplantation from deceased donors, older donor and recipient age, shorter survival of the first graft in non-sensitised recipients, higher PRA levels (1%-100%), and an increasing number of HLA-DR mismatches were associated with an increased probability of graft failure and death with a functioning graft. Transplants performed in more recent years were also associated with better survival outcomes. IN PRACTICE: "Each subsequent kidney transplantation in pediatric recipients carried a higher risk of GF [graft failure], particularly in the first months post-transplant. After the second transplantation, older calendar year of KTx [kidney transplantation], deceased donor (DD), older donor and recipient age, and increasing HLA-DR mismatches were associated with a higher predicted GF and death with functioning graft," the authors wrote. "In DD kidney allocation schemes, 2 HLA-DR mismatches should be avoided," they added. SOURCE: This study was led by Ferran Coens, Ghent University Hospital, Ghent, Belgium. It was published online on August 07, 2025, in Pediatric Nephrology. LIMITATIONS: This study had substantial missing data for HLA mismatches in living donor transplants, limiting the analysis of HLA mismatches to deceased donor kidney transplant recipients alone. Additionally, the analysis did not adjust for certain relevant peri- and post-transplant predictors of graft failure, such as cold and warm ischaemia time, socioeconomic status, and allograft rejection. DISCLOSURES: The registry involved in this study received funding through a grant from the Dietmar Hopp Stiftung, the European Society for Paediatric Nephrology, the German Society for Pediatric Nephrology, and other sources. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
